The Efficacy of an Over-the-Counter Multivitamin and Mineral Supplement to Prevent Infections in Patients With Inflammatory Bowel Disease in Remission With Immunomodulators and/or Biological Agents: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

This was a single-center, randomized, double-blind, placebo-controlled clinical trial to compare a multivitamin and mineral supplement (supplemented group) vs identical-in-appearance placebo (placebo group) in a total of 320 non-vitamin-deficient patients with IBD (Crohn's disease or ulcerative colitis) in remission with immunomodulators, biologic therapy, or combination therapy.

Why It Was Studied

Malnutrition and vitamin or mineral deficiencies are common among patients with IBD.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Copper (Supplement), giving a reference point.

What Was Measured

PubMed files the paper under topics including Vitamins, Dietary Supplements, Inflammatory Bowel Diseases, Minerals, Immunomodulating Agents, Infections and Crohn Disease.

The authors tagged it with the keywords Crohn’s disease, biologicals, immunomodulators, ulcerative colitis infection and vitamin and mineral supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Inflammatory bowel diseases), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.